Chinese Neurosurgical Journal (Oct 2022)

Multimodality treatment for brain arteriovenous malformation in Mainland China: design, rationale, and baseline patient characteristics of a nationwide multicenter prospective registry

  • Yu Chen,
  • Heze Han,
  • Li Ma,
  • Ruinan Li,
  • Zhipeng Li,
  • Debin Yan,
  • Haibin Zhang,
  • Kexin Yuan,
  • Ke Wang,
  • Yang Zhao,
  • Yukun Zhang,
  • Weitao Jin,
  • Runting Li,
  • Fa Lin,
  • Xiangyu Meng,
  • Qiang Hao,
  • Hao Wang,
  • Xun Ye,
  • Shuai Kang,
  • Hengwei Jin,
  • Youxiang Li,
  • Dezhi Gao,
  • Shibin Sun,
  • Ali Liu,
  • Shuo Wang,
  • Xiaolin Chen,
  • Yuanli Zhao

DOI
https://doi.org/10.1186/s41016-022-00296-y
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background Brain arteriovenous malformation (AVM) is an important cause of hemorrhagic stroke in young adults, which can lead to severe neurological impairment. The registry of Multimodality treatment for brain ArTeriovenous malformation in mainland CHina (MATCH) is a national prospective registry to identify the natural history of AVMs in Asian population; to investigate traditional and emerging hemorrhagic predictors; and to explore the superiority of the multidisciplinary assessment in improving the long-term outcomes. Methods Consecutive AVM patients will be enrolled from 52 participating hospitals in mainland China. Baseline demographic, clinical and imaging data will be collected prospectively. Conservation, microsurgery, embolization, stereotactic radiosurgery (SRS), and multimodal strategies are all included in this study. Patients will be divided into experimental and control group according to whether the treatment protocols are formulated by multidisciplinary team. Neurofunctional status, subsequent hemorrhage, seizure, and novel neurofunctional deficit will be queried at 3 months, annually (1 and 2 years), 3 years, and 10 years follow-up. Results Between August 2011 and April 2021, 3241 AVMs were enrolled in 11 participating sites. Among them, 59.0% were male with an average age of 28.4 ± 14.6 years, 61.2% had rupture history and 2268 hemorrhagic events occurred before admission. The median Spetzler-Martin grade and Lawton-Young grade was 3 and 5, respectively. Microsurgery is the dominant strategy (35.7%), with a similar proportion of embolization, SRS, and a combination of both (12.7%; 14.8%; 11.8%; respectively). Among them, 15.43% underwent multidisciplinary assessment and received standardized treatment. At the most recent follow-up, 7.8% were lost and the median follow-up duration was 5.6 years. Conclusions The MATCH study is a large-sample nationwide prospective registry to investigate multimodality management strategy for AVMs. Data from this registry may also provide the opportunity for individualized risk assessment and the development of optimal individual management strategies. Trial registration ClinicalTrials.gov Registry ( NCT04572568 ).

Keywords